1. Home
  2. News
Company News Media Coverage
wAMD DRUG PROJECT HXP056 COMPLETED ENROLLMENT FOR PHASE I CLINICAL STUDY AND INITIATED PHASE 2 STUDY
2026-03-24

wAMD DRUG PROJECT HXP056 COMPLETED ENROLLMENT FOR PHASE I CLINICAL STUDY AND INITIATED PHASE 2 STUDY

More
2026-03-09

More
2025-10-20

More
Information disclosure column on responsibility for the prevention and control of hazardous waste pollution
2024-07-17

Information disclosure column on responsibility for the prevention and control of hazardous waste pollution

More
Good news! Amlodipine atorvastatin calcium tablets won the bid for the eighth batch of national centralized drug procurement
2023-03-29

Good news! Amlodipine atorvastatin calcium tablets won the bid for the eighth batch of national centralized drug procurement

Haixi New Pharmaceutical has passed the consistency evaluation of generic drugs. The product amlodipine atorvastatin calcium tablets (trademark name: Haihuitong®) has won the first place.
More
Announcement of the overall change of Fujian Haixi New Drug Creation Co., Ltd. to a limited company
2022-11-18

Announcement of the overall change of Fujian Haixi New Drug Creation Co., Ltd. to a limited company

With the approval of Fujian Provincial Market Supervision and Administration, from November 15, 2022, Fujian Haixi New Pharmaceutical Creation Co., Ltd. has been changed to Fujian Haixi New Pharmaceutical Creation Co., Ltd.
More
About Us
Technology
Product
News
Investor
Attract Talents
Contact Us

Fujian Haixi New Pharmaceutical Creation Co., Ltd. Fujian ICP Record No. 12015727 Internet Drug Information Service Qualification Certificate No.: (Min) - Non-operating-2023-0063

Some of the text and pictures on this site are from the Internet and are only used for sharing and learning. If your rights and interests are infringed, please inform us in time, and this site will deal with or replace them in time.